Home › Cases › Hyponatraemia in Heart Failure
Hyponatraemia
Hyponatraemia in Heart Failure
6 questions
Question 1 · Aetiology
Correct answer: SIADH secondary to heart failure — perceived underfilling activates ADH inappropriately
Why
Heart failure causes SIADH-like physiology: perceived arterial underfilling → ADH release → water retention → dilutional hyponatraemia. Features: concentrated urine (osmolality >100), urine Na+ can be variable. Despite oedema, patient is 'functionally hypovolaemic'.
Key point
Heart failure → perceived underfilling → inappropriate ADH → dilutional hyponatraemia. SIADH physiology.
Question 2 · Symptoms assessment
Correct answer: Symptoms (seizure, coma, vomiting) = severe = treat urgently. Asymptomatic or mild = correct slowly
Why
Hyponatraemia severity is symptom-based, not purely numerical. Severe (seizure, GCS <8, coma, cardiorespiratory arrest) = 150ml 3% saline over 20 mins. Moderate (vomiting, confusion, drowsiness) = slower correction. Mild symptoms (nausea, headache) = restrict fluids. Asymptomatic: correct very slowly.
Key point
Hyponatraemia severity = symptoms, not just Na+ number. Seizure/coma = urgent 3% saline. Asymptomatic = slow.
Question 3 · Rate of correction
Correct answer: Maximum 10 mmol/L in 24h, ideally 8-10. Never >12 mmol/L in 24h. No limit in acute (<48h)
Why
Osmotic demyelination syndrome (ODS), formerly central pontine myelinolysis: devastating complication from too-rapid correction of chronic hyponatraemia. Brain adapts to low Na+ over >48h by losing osmoles. Rapid correction → pontine myelin destruction → locked-in syndrome, quadriplegia, death.
Key point
Chronic hyponatraemia: max 10 mmol/L in 24h. Faster = osmotic demyelination (ODS). Brain adapts slowly.
Question 4 · Treatment in heart failure
Correct answer: Fluid restriction (750-1000ml/day), optimise heart failure treatment. Consider vaptan (tolvaptan) under specialist guidance
Why
HF hyponatraemia: fluid restriction (750-1000ml/day) first. Optimise HF treatment (ACEi, beta-blockers). Tolvaptan (V2 receptor antagonist — vasopressin antagonist) licensed for hypervolaemic/euvolaemic hyponatraemia but specialist use only, significant side effects. Avoid IV saline in fluid-overloaded HF.
Key point
HF hyponatraemia: fluid restriction + optimise HF. No IV saline in overloaded patient. Tolvaptan specialist use.
Question 5 · Monitoring
Correct answer: U&E 4-hourly for first 24h (correct if overcorrecting). Daily thereafter. Na+ target rise <10 in 24h
Why
Hyponatraemia monitoring: frequent Na+ measurements to ensure rate of rise within safe limits (max 10 mmol/L/24h). If Na+ rises too fast: DDAVP (desmopressin) can be given to slow correction. Active overcorrection management.
Key point
4-hourly Na+ monitoring. If rising too fast: DDAVP to slow it. Max 10 mmol/24h — ceiling, not target.
Question 6 · Overcorrection risk factors
Correct answer: Malnourished, alcohol excess, liver failure, hypokalaemia — these patients have extra osmolar depletion vulnerability
Why
ODS highest risk: alcoholism, malnutrition, liver disease, hypokalaemia — these cause additional osmolar depletion beyond just sodium. Any chronic hyponatraemia. Correct hypokalaemia alongside sodium — K+ replacement raises effective Na+ level.
Key point
ODS highest risk: alcohol, malnutrition, liver failure, hypokalaemia. Correct K+ alongside — it raises Na+ too.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.